Neurostimulation Methods in the Treatment of Depression: A Comparison of rTMS, tDCS, and Venlafaxine Using a Pooled Analysis of Two Studies
Status PubMed-not-MEDLINE Jazyk angličtina Země Nový Zéland Médium electronic-ecollection
Typ dokumentu časopisecké články
PubMed
34093015
PubMed Central
PMC8169053
DOI
10.2147/ndt.s303226
PII: 303226
Knihovny.cz E-zdroje
- Klíčová slova
- MDD, efficacy, major depressive disorder, rTMS, repetitive transcranial magnetic stimulation, tDCS, transcranial direct-current stimulation, treatment, venlafaxine,
- Publikační typ
- časopisecké články MeSH
BACKGROUND: There are no head-to-head studies comparing the antidepressant effect of transcranial direct current stimulation (tDCS) with repetitive transcranial magnetic stimulation (rTMS). This pooled analysis compared indirectly the antidepressant efficacy and acceptability of rTMS, tDCS, and the antidepressant venlafaxine (VNF) extended-release. METHODS: The analysis (n=117, both patients with treatment-resistant depression (TRD) and non-TRD were included) examined pooled data from two 4-week, single-centered, two-armed, double-blind, randomized studies (EUDRACT n. 2005-000826-22 and EUDRACT n. 2015-001639-19). The antidepressant efficacy of right-sided low-frequency rTMS (n=29) vs VNF (n=31) and left-sided anodal tDCS (n=29) vs VNF (n=28) was evaluated. The primary outcome was a change in the Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to the treatment endpoint at week 4. The response was defined as a ≥50% reduction in the MADRS score and remission as the MADRS score ≤10 points, both were calculated for the primary treatment endpoint at week 4. RESULTS: Mean change in total MADRS scores from baseline to week 4 was 7.0 (95% CI, 4.8-9.1) points in the rTMS group, 7.6 (95% CI, 5.5-9.8) in the tDCS group, and 8.9 (95% CI, 7.4-10.4) among patients in the VNF group, a non-significant difference (F(2111)=0.62, p=0.54). Similarly, neither the response rates nor remission rates for rTMS (response 31%; remission 17%), tDCS (24%, 17%), or VNF (41%; 27%) significantly differed among treatment groups (χ 2=2.59, p=0.28; χ 2=1.66, p=0.44). Twenty patients (17%) dropped out of the studies in a similar proportion across groups (rTMS 3/29, tDCS 6/29, VNF 11/59, χ 2=1.41, p=0.52). CONCLUSION: Our current analysis found a comparable efficacy and acceptability in all three treatment modalities (rTMS, tDCS, and VNF) and clinical relevance for the acute treatment of major depressive disorder.
Zobrazit více v PubMed
Murray CJL, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–2191. PubMed PMC
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi:10.1016/S0140-6736(17)32802-7 PubMed DOI PMC
Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):572–579. doi:10.1001/archgenpsychiatry.2011.2044 PubMed DOI PMC
Arroll B, Chin WY, Martis W, et al. Antidepressants for treatment of depression in primary care: a systematic review and meta-analysis. J Prim Health Care. 2016;8(4):325–334. doi:10.1071/HC16008 PubMed DOI
Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–1242. doi:10.1056/NEJMoa052963 PubMed DOI
Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M. Association between antidepressant side effects and functional impairment in patients with major depressive disorders. Psychiat Res. 2013;210(1):127–133. doi:10.1016/j.psychres.2013.05.007 PubMed DOI
McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):35. doi:10.4088/JCP.16cs10905 PubMed DOI PMC
Gaynes BN, Lloyd SW, Lux L, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(5):477–U196. doi:10.4088/JCP.13r08815 PubMed DOI
Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med. 2014;44(2):225–239. doi:10.1017/S0033291713000512 PubMed DOI
Cao X, Deng CS, Su XL, Guo Y. Response and remission rates following high-frequency vs. low-frequency repetitive transcranial magnetic stimulation (rTMS) over right DLPFC for treating major depressive disorder (MDD): a meta-analysis of randomized, double-blind trials. Front Psychiatry. 2018;9. doi:10.3389/fpsyt.2018.00413 PubMed DOI PMC
Chen JJ, Zhou CJ, Wu B, et al. Left versus right repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomised controlled trials. Psychiat Res. 2013;210(3):1260–1264. doi:10.1016/j.psychres.2013.09.007 PubMed DOI
Berlim MT, Van den Eynde F, Daskalakis ZJ. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacol. 2013;38(4):543–551. doi:10.1038/npp.2012.237 PubMed DOI PMC
Milev RV, Giacobbe P, Kennedy SH, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments. Can J Psychiatry. 2016;61(9):561–575. doi:10.1177/0706743716660033 PubMed DOI PMC
Berlim MT, Van den Eynde F, Daskalakis ZJ. Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. J Psychiatr Res. 2013;47(1):1–7. doi:10.1016/j.jpsychires.2012.09.025 PubMed DOI
Shiozawa P, Fregni F, Bensenor IM, et al. Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis (vol 17, pg 1443, 2014). Int J Neuropsychopharmacol. 2014;17(9):1539. doi:10.1017/S1461145714000807 PubMed DOI
Meron D, Hedger N, Garner M, Baldwin DS. Transcranial direct current stimulation (tDCS) in the treatment of depression: systematic review and meta-analysis of efficacy and tolerability. Neurosci Biobehav Rev. 2015;57:46–62. doi:10.1016/j.neubiorev.2015.07.012 PubMed DOI
Brunoni AR, Moffa AH, Fregni F, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016;208(6):522. doi:10.1192/bjp.bp.115.164715 PubMed DOI PMC
Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY. Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: a systematic review and meta-analysis of randomised sham-controlled trials. Neurosci Biobehav Rev. 2018;92:291–303. doi:10.1016/j.neubiorev.2018.05.015 PubMed DOI
Moffa AH, Martin D, Alonzo A, et al. Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: an individual patient data meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99. PubMed
Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. J Affect Disord. 2009;118(1–3):94–100. doi:10.1016/j.jad.2009.01.032 PubMed DOI
Bares M, Brunovsky M, Stopkova P, Hejzlar M, Novak T. Transcranial direct-current stimulation (tDCS) versus venlafaxine ER in the treatment of depression: a randomized, double-blind, single-center study with open-label, follow-up. Neuropsychiatr Dis Treat. 2019;15:3003–3014. doi:10.2147/NDT.S226577 PubMed DOI PMC
American Psychiatric Association. Diagnostic Criteria from DSM-IV-TR. American Psychiatric Association; 2000.
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33. PubMed
Montgomery SA, Asberg M. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(Apr):382–389. doi:10.1192/bjp.134.4.382 PubMed DOI
Guy W. Clinical global impression. Assessment Man Psychopharmacol. 1976;217–222.
Beck AT, Rial WY, Rickels K. Short form of depression inventory - cross-validation. Psychol Rep. 1974;34(3):1184–1186. doi:10.1177/003329417403403s01 PubMed DOI
Baeken C, Brem AK, Arns M, et al. Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions. Curr Opin Psychiatry. 2019;32(5):409–415. doi:10.1097/YCO.0000000000000533 PubMed DOI PMC
Loo CK, Husain MM, McDonald WM, et al. International randomized-controlled trial of transcranial direct current stimulation in depression. Brain Stimul. 2018;11(1):125–133. doi:10.1016/j.brs.2017.10.011 PubMed DOI
Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019;364. PubMed PMC
Razza LB, Palumbo P, Moffa AH, et al. A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes. Depress Anxiety. 2020;37(7):594–608. doi:10.1002/da.23004 PubMed DOI
Brunelin J, Jalenques I, Trojak B, et al. The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT. Brain Stimul. 2014;7(6):855–863. doi:10.1016/j.brs.2014.07.040 PubMed DOI
Rigonatti SP, Boggio PS, Myczkowski ML, et al. Transcranial direct stimulation and fluoxetine for the treatment of depression. Eur Psychiatry. 2008;23(1):74–76. doi:10.1016/j.eurpsy.2007.09.006 PubMed DOI
Brunoni AR, Valiengo L, Baccaro A, et al. The sertraline vs electrical current therapy for treating depression clinical study results from a factorial, randomized, controlled trial. JAMA Psychiat. 2013;70(4):383–391. doi:10.1001/2013.jamapsychiatry.32 PubMed DOI
Brunoni AR, Moffa AH, Sampaio B, et al. Trial of electrical direct-current therapy versus escitalopram for depression. N Engl J Med. 2017;376(26):2523–2533. doi:10.1056/NEJMoa1612999 PubMed DOI
Goerigk SA, Padberg F, Buhner M, et al. Distinct trajectories of response to prefrontal tDCS in major depression: results from a 3-arm randomized controlled trial. Neuropsychopharmacol. 2021;46(4):774–782. doi:10.1038/s41386-020-00935-x PubMed DOI PMC
Alonzo A, Fong J, Ball N, Martin D, Chand N, Loo C. Pilot trial of home-administered transcranial direct current stimulation for the treatment of depression. J Affect Disord. 2019;252:475–483. doi:10.1016/j.jad.2019.04.041 PubMed DOI
Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol. 2020;131(2):474–528. PubMed
Dedoncker J, Brunoni AR, Baeken C, Vanderhasselt MA. A systematic review and meta-analysis of the effects of transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex in healthy and neuropsychiatric samples: influence of stimulation parameters. Brain Stimul. 2016;9(4):501–517. doi:10.1016/j.brs.2016.04.006 PubMed DOI
Kiebs M, Hurlemann R, Mutz J. Repetitive transcranial magnetic stimulation in non-treatment-resistant depression. Br J Psychiatry. 2019;215(2):445–446. doi:10.1192/bjp.2019.75 PubMed DOI
Furukawa TA, Cipriani A, Atkinson LZ, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016;3(11):1059–1066. doi:10.1016/S2215-0366(16)30307-8 PubMed DOI
Razza LB, Moffa AH, Moreno ML, et al. A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:105–113. doi:10.1016/j.pnpbp.2017.10.016 PubMed DOI
Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry. 2010;71(3):270–279. doi:10.4088/JCP.08r045116blu PubMed DOI
Kennedy SH, Lam RW, McIntyre RS, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. doi:10.1177/0706743716659417 PubMed DOI PMC
Henssler J, Kurschus M, Franklin J, Bschor T, Baethge C. Trajectories of acute antidepressant efficacy: how long to wait for response? A systematic review and meta-analysis of long-term, placebo-controlled acute treatment trials. J Clin Psychiatry. 2018;79(3). PubMed
Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2016;9(3):336–346. doi:10.1016/j.brs.2016.03.010 PubMed DOI PMC